Cardiovascular Disease CVD Constitutes a Significant Health Challenge for Individuals With Type 2 Diabetes Mellitus T2DM, Affecting Approximately 32% of This Population and Contributing Significantly to Global Mortality.Visceral Adipose Tissue VAT Accumulation Has Been Recognize

NCT07204782 | Not Yet Recruiting DMC

• 1 other identifier: Visceral adiposity indices
• Study Type: observational
• Target: 238
• Locations: 1 country
• Sites: 1

Brief Summary

calculate cardiovascular risk scores in type 2 DM patients, then estimate its association with new visceral adipose tissue indices

Conditions

Diabete Mellitus

Keywords

cardiovascular risk scores; visceral adiposity indices; diabetes mellitus; VAT; LAP

Outcome Measures

Primary Outcomes (1)

• The prevalence of elevated 10-year cardiovascular risk scores among patients with type 2 diabetes mellitus.

  Measurement tool: WHO cardiovascular risk chart Unit of measure: % of patients with ≥10% predicted 10-year cardiovascular risk

  1 YEAR

Secondary Outcomes (1)

• The correlation between cardiovascular risk scores and non-invasive visceral adiposity indices (such as LAP and VAI).

  1 YEAR

Other Outcomes (1)

• The relationship between cardiovascular risk and clinical/lifestyle factors (e.g., duration of diabetes, BMI, physical activity, smoking, blood pressure, lipid profile).

  1 YEAR

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Diabetic patients attending Assiut university

You may qualify if:

• Adult patients ≥40 years old attending the out patients clinics
• Patients diagnosed with type 2 diabetes mellitus

You may not qualify if:

• Patient with a history of cardiovascular events
• Patient with type 1 diabetes or gestational diabetes.
• Pregnant women.
• Hypothyroidism,
• Cushing disease
• polycystic ovarian syndrome.
• Congestive heart failure
• chronic liver disease
• chronic kidney disease,
• cancer
• Current use of steroids, birth control pills, antipsychotics, antidepressants, epilepsy drugs.
• Patients with physical deformities or conditions affecting anthropometric measurements.

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

Assiut university

Asyut, Egypt

Location

Related Publications (3)

• Tawfik MY, Mohamed SF, Elotla SF. Association of novel visceral obesity indices with 10-year risk of major cardiovascular events in patients with type 2 diabetes mellitus. J Egypt Public Health Assoc. 2025 May 30;100(1):12. doi: 10.1186/s42506-025-00188-w.

  PMID: 40445502 BACKGROUND

• Wang L, Liu S, Ke J, Cao B, Wang D, Zhao Q, Gong H, Fang Y, Zheng Z, Yu C, Wu N, Ma Y, Yu K, Yang L, Zhao D. Association between metabolic visceral fat score and left ventricular hypertrophy in individuals with type 2 diabetes. Diabetol Metab Syndr. 2025 Mar 6;17(1):81. doi: 10.1186/s13098-025-01648-1.

  PMID: 40050939 BACKGROUND

• Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018 Jun 8;17(1):83. doi: 10.1186/s12933-018-0728-6.

  PMID: 29884191 BACKGROUND

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident doctor

Study Record Dates

• First Submitted: September 20, 2025
• First Posted: October 2, 2025
• Study Start: December 1, 2025
• Primary Completion (Estimated): April 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: October 2, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)